Sentences with phrase «of share repurchase programs»

Liquidity options vary and may take the form of share repurchase programs or secondary marketplace transactions but are generally limited.

Templeton Dragon Fund, Inc., Templeton Russia and East European Fund, Inc., and Templeton Emerging Markets Fund Announce Modification of Share Repurchase Programs

«We are very pleased that MSG's board of directors and management have committed to pursue a plan to enhance value for all MSG shareholders through the combination of a share repurchase program and contemplated business spin - off... We look forward to the full and timely implementation of these plans,» JAT Capital Management LP said in an email to Reuters.

An earlier version of this story misstated the effective date of the share repurchase program.

Apple would have to gain just 8 % to reach the cuatro commas club (probably a little more because of its share repurchase program.

Royal Bank of Canada (RBC)(«RY» on TSX and NYSE) today announced the completion of its share repurchase program (the «Program»), as required by the conditions of the issuer bid exemption order issued to RBC by the Ontario Securities Commission on January 10, 2018...

Royal Bank of Canada (RBC)(«RY» on TSX and NYSE) today announced the completion of its share repurchase program (the «Program»),...

Royal Bank of Canada (RBC)(«RY» on TSX and NYSE) today announced the completion of its share repurchase program...

The company increased its dividend by 33 % and announced the start of a share repurchase program.

Not exact matches

In an open letter to Apple CEO Tim Cook, posted to Icahn's website Thursday, he outlined a share buyback program in which Apple would repurchase $ 150 billion of its own stock in order to improve company growth.

From the inception of our Stock Repurchase Program through April 27, 2018, we repurchased approximately 23.7 million shares of our common stock at an aggregate market value of approximately $ 1.5 billion.

Citigroup was the highlight after hours, doubling its quarterly dividend to 32 cents per common share and announcing a common stock repurchase program of up to $ 15.6 billion.

The company said it expects to use part of the proceeds to buy back shares and raised its repurchase program by $ 5 billion to $ 7.7 billion.

The company repurchased 1.6 million shares of common stock for $ 24.3 million during the first quarter under the company's $ 300 million share buyback program.

Here's some more color on returning cash to shareholders from Butters» note: «Share repurchase programs have become a very popular way of returning capital to shareholders over the years.

Maestri said that since Apple has now completed $ 275 billion of its $ 300 billion capital return program, including $ 200 billion in share repurchases, Apple will complete its original plan three quarters early, in June.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

During the third quarter, NIKE, Inc. repurchased a total of 14.6 million shares for approximately $ 962 million as part of the four - year, $ 12 billion program approved by the Board of Directors in November 2015.

In its quarterly report on Tuesday, Apple said it would earmark $ 100 billion for a new share repurchase program, succeeding a $ 210 billion buyback program that started in 2012 and will wrap up this quarter - roughly nine months ahead of schedule.

The board of directors of T. Rowe Price Group approved adding another 10 million shares to it stock repurchase plan, expanding that program to 21 million shares, the Baltimore - based money management firm announced Thursday.

Apple's stock buyback program isn't just bigger than those of other companies, it's also better at doing what investors want share repurchases to do.

Between 1984 and 1993, Coca - Cola acquired 570 million shares of its own stock through its stock repurchase program, reducing the shares outstanding from 3.174 billion to 2.604 billion.

In addition, the company announced that its Board of Directors has authorized a share repurchase program under which the company may repurchase up to 3,500,000 shares of its outstanding common stock.

According to disclosures published by Grayscale in 2015, the program's repurchases took place at the same time that shares were being created by the trust — in violation of Regulation M.

The company's board of directors has authorized the repurchase of an additional 2 million shares of its common stock, bringing the total share authorization under its share repurchase program to approximately 3.4 million shares.

HP repurchases shares of its stock under an ongoing program to manage the dilution created by shares issued under employee stock plans as well as to repurchase shares opportunistically.

Following the stress tests, Bank of America boosted its dividend by 50 % and added a $ 5 billion share repurchase program to boot.

With the newly announced $ 100 billion share repurchase program, it's clear that Apple is running out of ideas.

A shareholder proposal by Carl Icahn of a non-binding advisory resolution that the Company commit to completing not less than $ 50 billion of share repurchases during its 2014 fiscal year (and increase the authorization under its capital return program accordingly)(Proposal No. 10); and

Royal Bank of Canada (RBC)(«RY» on TSX and NYSE) today announced that it will repurchase shares under a specific share repurchase program (the «Program&rprogram (the «Program&rProgram»).

Dividends and share repurchases must be funded by domestic cash, and the Company has returned to shareholders or invested all of the domestic cash generated by its business and raised through the issuance of debt since the beginning of the program.

During fiscal 2014, the company repurchased 36.8 million shares as part of our stock repurchase program.

«RESOLVED, that the shareholders hereby approve, on an advisory basis, High River's proposal that Apple commit to completing not less than $ 50 billion of share repurchases during Apple's fiscal year ending September 27, 2014 (and increase the amount authorized for share repurchases under its Capital Return Program accordingly).»

Since the inception of the program through March 31, 2018, Select Medical has repurchased 35,924,128 shares at a cost of approximately $ 314.7 million, or $ 8.76 per share, which includes transaction costs.

A proposal by Carl Icahn of a non-binding advisory resolution that the Company commit to completing not less than $ 50 billion of share repurchases during its 2014 fiscal year (and increase the authorization under its capital return program accordingly)

2018.01.10 Royal Bank of Canada announces specific share repurchase programs as part of its normal course issuer bid Royal Bank of Canada (RBC)(«RY» on TSX and NYSE) today announced that it will repurchase shares under two specific share repurchase programs (the «Programs&raprograms as part of its normal course issuer bid Royal Bank of Canada (RBC)(«RY» on TSX and NYSE) today announced that it will repurchase shares under two specific share repurchase programs (the «Programs&raprograms (the «Programs&raPrograms»)...

2017.10.11 Royal Bank of Canada announces specific share repurchase program as part of its normal course issuer bid Royal Bank of Canada (RBC)(«RY» on TSX and NYSE) today announced that it will repurchase shares under a specific share repurchase program (the «Program&rprogram as part of its normal course issuer bid Royal Bank of Canada (RBC)(«RY» on TSX and NYSE) today announced that it will repurchase shares under a specific share repurchase program (the «Program&rprogram (the «Program&rProgram»).

By their very nature, forward - looking statements require us to make assumptions and are subject to inherent risks and uncertainties, which give rise to the possibility that our predictions, forecasts, projections, expectations or conclusions will not prove to be accurate, that our assumptions may not be correct and that our forward - looking statements, including statements about the specific share repurchase program forming part of the normal course issuer bid by Royal Bank of Canada, will not be achieved.

As a part of the stress tests, these banks must also seek regulatory approval to increase their dividends or authorize new share repurchase programs.

When a board of directors authorizes a share repurchase program, it typically states either the number of shares the company is interested in buying back or a dollar amount it will spend on its stock buyback.

Typically, when a company announced a stock buyback program, the prospect of repurchases boosts the share price.

Berkshire has an open - ended share repurchase program that authorizes management to repurchase shares if the stock price drops below a price - to - book ratio of 1.2 x.

In what could be called the «ultimate stock buyback program,» TPL is using multiple income streams to eventually repurchase all of its outstanding shares.

Medium Risk — Growth (M / GRW) Lower to average risk equities of companies with sound financials, consistent earnings growth, the potential for long - term price appreciation, a potential dividend yield, and / or share repurchase program.

Share Repurchase Program During the second quarter of 2014, the company repurchased 936,060 shares of its common stock at an average price of $ 55.56 per share for a total of approximately $ 52 milShare Repurchase Program During the second quarter of 2014, the company repurchased 936,060 shares of its common stock at an average price of $ 55.56 per share for a total of approximately $ 52 milshare for a total of approximately $ 52 million.

As well as missing revenue forecasts, Alibaba announced a $ 4 billion share repurchase program over two years, which it said was primarily aimed at offsetting the impact of the company's share - based compensation programs and other factors that could dilute the share price.

Since the launch of the program on October 20, 2013 through October 15, 2014, the company has repurchased nearly 3.4 million shares of the 3.5 million shares originally authorized.

Through July 22, 2014, the company has repurchased a total of nearly 2.5 million shares of its common stock for a total of $ 134 million since the launch of the program on October 20, 2013.

In the second quarter of 2014, the company repurchased 936,060 shares of its common stock under its share repurchase program for approximately $ 52 million.

Through July 22, 2014, the company has repurchased a total of nearly 2.5 million shares for a total of $ 134 million since the launch of the program in the fourth quarter of 2013.